3.4Impact Factor
4.9CiteScore
22 daysTime to First Decision

Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..

Current Oncology, Volume 17, Issue 11

July 2010 - 3 articles

Issues are regarded as officially published after their release is announced to the table of contents alert mailing list .
You may sign up for email alerts to receive table of contents of newly released issues.
PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.

Articles (3)

Select all

Review

59 Citations

854 Views

Adverse Events Associated with Anti-EGFR Therapies for the Treatment of Metastatic Colorectal Cancer

M. Fakih and
M. Vincent

Curr. Oncol.2010, 17(11), 18-30;https://doi.org/10.3747/co.v17is1.615

1 July 2010

The epidermal growth factor receptor (EGFR), a member of the ErbB family of receptor tyrosine kinases, plays an important role in the control of cell growth and differentiation. Disruption of its signaling leads to neoplastic cell proliferation, migr...

Full Article

Article

60 Citations

1,363 Views

15 Pages

Efficacy of the Monoclonal Antibody EGFR Inhibitors for the Treatment of Metastatic Colorectal Cancer

Marwan Fakih and
R. Wong

Curr. Oncol.2010, 17(11), III-XVII;https://doi.org/10.3747/co.v17is1.616

1 July 2010

Two anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (MoAbs) have been approved in Canada for the treatment of metastatic colorectal cancer (mCRC)—cetuximab, a mouse-human chimeric MoAb, and panitumumab, a fully human MoAb. This pap...

Full Article

Article

45 Citations

1,261 Views

10 Pages

KRAS Mutation Testing in the Treatment of Metastatic Colorectal Cancer with Anti-EGFR Therapies

D. Soulières,
W. Greer,
Anthony M. Magliocco,
D. Huntsman,
S. Young,
M.-S. Tsao and
Suzanne Kamel-Reid

Curr. Oncol.2010, 17(11), 31-40;https://doi.org/10.3747/co.v17is1.614

1 July 2010

Survival of patients with metastatic CRC (mCRC) has improved steadily over the past several decades, due largely to the development of new combinations of standard chemotherapy, as well as to the introduction of new targeted therapies. Among the avai...

Full Article

Get Alerted

Add your email address to receive forthcoming issues of this journal.

Curr. Oncol. - ISSN 1718-7729

Imprint

Download Flyer